We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: neoadjuvant chemotherapy
MedXY News
EnglishTag

neoadjuvant chemotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Neoadjuvant Chemotherapy with or without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Impact on Outcomes
General Surgerysurvival outcomesRadiotherapy

Neoadjuvant Chemotherapy with or without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Impact on Outcomes

By MedXY|Aug 31, 2026

A propensity-matched study shows adding radiotherapy to neoadjuvant chemotherapy improves pathologic response but does not enhance survival or reduce recurrence in resected pancreatic ductal adenocarcinoma.

Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 Trial
newsNiraparib
neoadjuvant chemotherapy

Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 Trial

By MedXY|Aug 21, 2026

The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer
newsovarian cancerinterval debulking surgery

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer

By MedXY|Aug 19, 2026

This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT find

Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial
newsneoadjuvant chemotherapyImmune Checkpoint Inhibition

Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial

By MedXY|Aug 18, 2026

The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a pos

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration
newsCT 影像high-grade serous ovarian cancer

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY|Jul 5, 2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and s

newsadvanced ovarian cancerPrehabilitation

Prehabilitation During Neoadjuvant Chemotherapy May Improve Surgery Eligibility and Chemotherapy Delivery in Advanced Ovarian Cancer

By MedXY|Aug 18, 2026

A matched-cohort study found that multimodal prehabilitation during neoadjuvant chemotherapy improved chemotherapy delivery and increased the chance of interval debulking surgery in advanced ovarian cancer, with the strongest benefits seen

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,
General Surgerybreast cancerDi căn hạch cổ

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

By MedXY|May 18, 2026

A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete

Should Some Colon Cancers Be Treated Before Surgery? What a New Trial Means for Patients
Gastroenterologycolon cancerMMR status

Should Some Colon Cancers Be Treated Before Surgery? What a New Trial Means for Patients

By MedXY|May 18, 2026

A major randomized trial found that chemotherapy before surgery did not improve 3-year disease-free survival in locally advanced colon cancer, but it still revealed important clues for more personalized treatment.

MRI-Guided Personalization of Chemotherapy for HER2-Positive Breast Cancer: Insights from the TRAIN-3 Trial
newsHER2-đương tính Ung thư vúneoadjuvant chemotherapy

MRI-Guided Personalization of Chemotherapy for HER2-Positive Breast Cancer: Insights from the TRAIN-3 Trial

By MedXY|Mar 2, 2026

The TRAIN-3 study reveals that using MRI to monitor treatment response allows for shorter chemotherapy durations in HER2-positive breast cancer patients, achieving high 3-year event-free survival while significantly reducing toxicity and im

Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy
General Surgerybreast cancerneoadjuvant chemotherapy

Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy

By MedXY|Jan 5, 2026

The OPBC-07/microNAC study suggests that axillary lymph node dissection can be safely omitted in many breast cancer patients with residual micrometastases post-neoadjuvant chemotherapy, provided nodal radiotherapy is used, though triple-neg

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
newsCarboplatinneoadjuvant chemotherapy

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

By MedXY|Dec 9, 2025

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
newsmFOLFIRINOXneoadjuvant chemotherapy

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

By MedXY|Nov 24, 2025

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxici

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis
Hematology-Oncologybreast cancerneoadjuvant chemotherapy

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

By MedXY|Oct 18, 2025

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?
Clinical Updatesbreast cancerclinical trial

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY|Sep 30, 2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities